Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Diab Vasc Dis Res · 2019 · PMC6613297 · PMID 31018682

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Pancreatitis and pancreatic cancer Although numerically infrequent, sitagliptin use was associated with a slightly higher risk of pancreatitis, and this was borderline significant, while the risk of pancreatic cancer was not significantly increased.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.